课题基金 / 基金详情

A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED

A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED
甲磺酸伊马替尼（格列卫）在 HIV 相关患者中的 II 期试验
批准号：
7606810
负责人：
RONALD T. MITSUYASU
金额：
$0.89万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-02-21 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7606810
关键词：
Computer Retrieval of Information on Scientific Projects DatabaseDrug KineticsEvaluationFundingGleevecGrantHIVImatinibImatinib mesylateImmunohistochemistryInstitutionPDGF inhibitionPatientsPhasePlatelet-Derived Growth Factor ReceptorResearchResearch PersonnelResistanceResourcesSourceUnited States National Institutes of Healthcytokineresearch clinical testingresponse

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective: Evaluation of clinical response Secondary Objectives ¿ Evaluation of inhibition of PDGF receptor as determined by immunohistochemistry. ¿ Evaluation of cytokine profiles pre- and post-imatinib therapy. ¿ Evaluation of pharmacokinetic profile of imatinib in HIV patients. ¿ Evaluation of mechanisms of primary and secondary resistance to imatinib therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)
海外基金